Phase I/II study of bortezomib-melphalan-prednisolone for previously untreated Japanese patients with multiple myeloma. - Wikidata - awgldk - TriplyDB

Phase I/II study of bortezomib-melphalan-prednisolone for previously untreated Japanese patients with multiple myeloma.

Phase I/II study of bortezomib-melphalan-prednisolone for previously untreated Japanese patients with multiple myeloma.

http://www.wikidata.org/entity/Q33406992

about

Trial Watch: Proteasomal inhibitors for anticancer therapy A phase I pharmacokinetic study of intraperitoneal bortezomib and carboplatin in patients with persistent or recurrent ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study.A prospective, open-label, multicenter, observational study to evaluate the efficacy and safety of bortezomib-melphalan-prednisone as initial treatment for autologous stem cell transplantation-ineligible patients with multiple myeloma Bortezomib, Melphalan, and Prednisone (VMP) Regimen for Multiple Myeloma Thalidomide-based induction regimens are as effective as bortezomib-based regimens in elderly patients with multiple myeloma with cereblon expression.Bortezomib plus dexamethasone vs thalidomide plus dexamethasone for relapsed or refractory multiple myeloma.

P2860

Q28082910-9783E943-F01B-487C-8FFD-A0B9FC96E65D Q30252871-EAC811B5-6A3E-4D29-9144-89CBD230DB54 Q33914056-EABF8515-7ECE-4998-848F-5874F592751F Q35063100-803342FF-9E4B-4A95-9A21-8BBC04F4A7BE Q39640777-469DE3A9-5651-4AD1-B77C-5B5496864197 Q52686509-46FBFE37-32A4-489B-9601-2C1CCA412B08

P2860

Phase I/II study of bortezomib-melphalan-prednisolone for previously untreated Japanese patients with multiple myeloma.

http://www.wikidata.org/entity/Q33406992

description

2013 nî lūn-bûn

@nan

2013 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Phase I/II study of bortezomib ...... atients with multiple myeloma.

@ast

Phase I/II study of bortezomib ...... atients with multiple myeloma.

@en

type

label

Phase I/II study of bortezomib ...... atients with multiple myeloma.

@ast

Phase I/II study of bortezomib ...... atients with multiple myeloma.

@en

prefLabel

Phase I/II study of bortezomib ...... atients with multiple myeloma.

@ast

Phase I/II study of bortezomib ...... atients with multiple myeloma.

@en

P1433

Q33406992-0D941828-330B-4739-AC90-3C2249621D91

P1476

Q33406992-AB9917A7-6D98-40FE-888F-81FA74B68E4C

P2093

Q33406992-03ADF656-E574-4B5D-A953-74557BF4A9C7

Q33406992-07F0058D-0F08-4CF1-B5C1-7541C1A65E90

Q33406992-0F06CA8D-B617-4551-A62A-5CE6BA4803D7

Q33406992-13DD8D0E-A090-4947-82F5-8F982D4D5358

Q33406992-2DA79AF8-2FD8-4A42-892D-7E9611DCB2E6

Q33406992-362987FE-740F-41CB-9921-A987D53ACCEF

Q33406992-3E972498-779D-492F-9F3E-747F407CEAAE

Q33406992-5BA1D29D-62DA-4BAE-80F8-AE49715FA2EA

Q33406992-631B9E6C-072F-476C-AB9C-F5900784D0EF

Q33406992-6BEC714F-2D1C-4FBC-B196-EE4D7D8B4585

P2860

Q33406992-17DABFBA-783C-417F-80E1-BCA46A6A16EE

Q33406992-201BEB4E-3DC3-47B9-B04D-D17B2F68602C

Q33406992-2C08E499-45AC-4D0C-9E69-EE77CBE57A44

Q33406992-39CB6CC5-1C6D-47F7-AE64-F268D70DB4C0

Q33406992-49C3B02F-14CB-415D-B452-0DF172C5FB6E

Q33406992-51F7FE02-CBCA-4CDC-B89E-99C8BDE3193E

Q33406992-5CD904FF-44EF-43FD-BDDC-4B791423056E

Q33406992-60739714-84A7-42F7-AE70-B75C58FDA770

Q33406992-61F1688F-9A86-4B38-B841-8759D724483E

Q33406992-84953812-3AC9-4A98-9866-7A96AB8D70FE

P304

Q33406992-CF198525-2E8D-4060-8FD9-5B03FAE146AB

P31

Q33406992-E712DD67-BD35-4C20-97AD-2EB3EA9420FD

P356

Q33406992-D65DBE36-7850-43FF-9106-C06B245C5A34

P433

Q33406992-6B15F370-B6C4-4CC9-A864-4423E933964F

P478

Q33406992-0D87E686-C8AF-43B5-B227-BB6F21293274

P577

Q33406992-AF88C48B-A3DB-46C2-878F-0886B625A213

P5875

Q33406992-660C2148-C486-42A6-A4E4-73D0395FED5B

P698

Q33406992-C95B1CDE-F77F-4CEA-8BBE-74A48699BECA

P356

P1433

P1476

Phase I/II study of bortezomib ...... atients with multiple myeloma.

@en

P2093

Akira Sakai

http://www.w3.org/2001/XMLSchema#string

Harumi Y Mukai

http://www.w3.org/2001/XMLSchema#string

Kazuteru Ohashi

http://www.w3.org/2001/XMLSchema#string

Kensei Tobinai

http://www.w3.org/2001/XMLSchema#string

Kenshi Suzuki

http://www.w3.org/2001/XMLSchema#string

Kiyoshi Ando

http://www.w3.org/2001/XMLSchema#string

Kosei Matsue

http://www.w3.org/2001/XMLSchema#string

Masami Ishii

http://www.w3.org/2001/XMLSchema#string

Michinori Ogura

http://www.w3.org/2001/XMLSchema#string

Morio Matsumoto

http://www.w3.org/2001/XMLSchema#string

P2860

Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study.

High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma.

Multiple myeloma.

Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant.

Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.

Multiple myeloma: 2011 update on diagnosis, risk-stratification, and management.

Guidelines for the diagnosis and management of multiple myeloma 2011.

Lung injury associated with bortezomib therapy in relapsed/refractory multiple myeloma in Japan: a questionnaire-based report from the "lung injury by bortezomib" joint committee of the Japanese society of hematology and the Japanese society of clin

Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial.

Efficacy and safety of once-weekly bortezomib in multiple myeloma patients.

P304

912-919

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/CAS.12172

http://www.w3.org/2001/XMLSchema#string

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

104

http://www.w3.org/2001/XMLSchema#string

P577

2013-05-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

236190811

http://www.w3.org/2001/XMLSchema#string

P698

23574271

http://www.w3.org/2001/XMLSchema#string